Completed PHASE4 INTERVENTIONAL NCT00494897

PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Sponsor: PETHEMA Foundation

Interventions Asparaginase Cyclophosphamide Cytarabine Daunorubicin Intrathecally treatment Mercaptopurine Methotrexate Prednisone Vincristine

Updated 6 times since 2017 Last updated: May 15, 2009 Started: Jun 30, 1996 Primary completion: May 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00494897, this PHASE4 trial focuses on Acute Lymphoblastic Leukemia and remains completed. Sponsored by PETHEMA Foundation, it has been updated 6 times since 1996, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PETHEMA Foundation

Data source: PETHEMA Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Albacete, Spain , Alicante, Spain , Badajoz, Spain , Badalona, Spain , Barcelona, Spain , Basurto, Spain , Cadiz, Spain , Castelló, Spain , Ciudad Real, Spain and 44 more locations